Emcure Pharmaceuticals Ltd. announced robust financial results for the third quarter of the 2025-26 fiscal year, marking significant growth across both domestic and international businesses. The company reported a notable rise in profitability and topline performance, underpinned by diversified portfolio strength and strategic initiatives.
In the quarter ended December 31, 2025, Emcure’s revenue from operations climbed 20.4 % year-on-year to Rs. 2,363 crore, reflecting broad-based demand across markets. This growth was supported by sustained momentum in chronic therapy segments domestically and strong contributions from key global markets.
The company achieved a significant 48.2 % year-on-year increase in Profit After Tax (PAT) to Rs. 231 crore, even after accounting for a Rs. 38 crore exceptional expense related to new labour code provisions. Operating leverage improvements and an expanded EBITDA helped lift profitability metrics during the period.
Emcure’s EBITDA for the quarter stood at Rs. 460 crore, up 27.2 % YoY, with margins improving to 19.5 %. The rise in margins underscores the company’s focus on optimized cost management and profitable growth.
Breaking down performance by geography, domestic business sales grew 15.4 % to Rs. 1,025 crore, driven by strong performance across chronic therapies such as cardiovascular and diabetes care as well as the launch of new products. Meanwhile, international sales surged 24.5 % to Rs. 1,338 crore, with the Rest of the World (RoW) segment up over 30 % on the back of gains in both ARV and non-ARV categories.
A key highlight of the quarter was the introduction of Poviztra®, a biological injectable semaglutide launched in India through a partnership with Novo Nordisk, positioning Emcure in the fast-growing obesity-care segment. The company also reported strong traction for other differentiated products across its global markets.
Satish Mehta, CEO and Managing Director, emphasized that all business verticals “outpaced industry growth” during the quarter, reinforcing Emcure’s strategic focus on innovation, portfolio expansion, and profitability enhancement. Continued investments in R&D, product launches and market expansion are expected to sustain growth over the medium term.
